scholarly journals Comparative Efficacy and Clinical Outcomes of Haploidentical Stem Cell Transplantation to Other Stem Sources for Treatment in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: A Systematic Review and Meta-Analysis

2020 â—½  
Vol 29 â—½  
pp. 096368972090496 â—½  
Author(s):  
Chutima Kunacheewa â—½  
Patompong Ungprasert â—½  
Ployploen Phikulsod â—½  
Surapol Issaragrisil â—½  
Weerapat Owattanapanich
Keyword(s):  
Systematic Review â—½  
Acute Myeloid Leukemia â—½  
Stem Cell â—½  
Stem Cell Transplantation â—½  
Myelodysplastic Syndrome â—½  
Cell Transplantation â—½  
Myeloid Leukemia â—½  
Meta Analysis â—½  
Comparable Efficacy â—½  
Acute Myeloid

The use of allogeneic hematopoietic stem cell transplantation (HSCT) is recommended during the first complete remission of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). However, only 30% of these cases have fully matched sibling donors (MSDs). Alternatively, matched unrelated donors (MUDs) and haploidentical (haplo) donors from first-degree relatives increase the access to transplantation, with some reported differences in outcomes. The current systematic review and meta-analysis was conducted with the aim of summarizing the results of those studies to compare the efficacy and toxicity of MSD-HSCT and MUD-HSCT versus haplo-HSCT for patients with AML or MDS. Articles published before September 15, 2018, were individually searched for in two databases (MEDLINE and EMBASE) by two investigators. The effect estimates and 95% confidence intervals (CIs) from each eligible study were combined using the Mantel–Haenszel method. A total of 14 studies met the eligibility criteria and were included in the meta-analysis. The overall survival rates were not significantly different between the groups, with pooled odds ratios of the chance of surviving at the end of the study when comparing haplo-HSCT to MSD-HSCT and comparing haplo-HSCT to MUD-HSCT of 0.85 (95% CI: 0.70 to 1.04; I 2 = 0%) and 1.12 (95% CI: 0.89 to 1.41; I 2 = 33%), respectively. The pooled analyses of other outcomes also showed comparable results, except for the higher grade 2 to 4 acute graft-versus-host disease (GvHD) for patients who received haplo-HSCT than those who received MSD-HSCT, and the better GvHD-free, relapse-free survival and the lower chronic GvHD than the patients in the MUD-HSCT group. These observations suggest that haplo-HSCT is a reasonable alternative with comparable efficacy if MSD-HSCT and MUD-HSCT cannot be performed. Nonetheless, the primary studies included in this meta-analysis were observational in nature, and randomized-controlled trials are still needed to confirm the efficacy of haplo-HSCT.

scholarly journals Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older

2005 â—½  
Vol 11 (10) â—½  
pp. 764-772 â—½  
Author(s):  
Vikas Gupta â—½  
Andrew Daly â—½  
Jeffrey H. Lipton â—½  
Wanda Hasegawa â—½  
Kathy Chun â—½  
...  
Keyword(s):  
Acute Myeloid Leukemia â—½  
Stem Cell â—½  
Stem Cell Transplantation â—½  
Myelodysplastic Syndrome â—½  
Cell Transplantation â—½  
Myeloid Leukemia â—½  
Nonmyeloablative Stem Cell Transplantation â—½  
Acute Myeloid

scholarly journals Maintenance with Hypomethylating Agents after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis

2021 â—½  
Author(s):  
Smith Kungwankiattichai â—½  
â—½  
Ben Ponvilawa â—½  
Claudie Roy â—½  
Pattaraporn Tunsing â—½  
...  
Keyword(s):  
Acute Myeloid Leukemia â—½  
Stem Cell â—½  
Stem Cell Transplantation â—½  
Cell Transplantation â—½  
Myeloid Leukemia â—½  
Meta Analysis â—½  
Hypomethylating Agents â—½  
Eligibility Criteria â—½  
Hematopoietic Stem â—½  
Acute Myeloid

Review question / Objective: P: Patients with AML or MDS after allo-SCT; I: Hypomethylating agents after allo-SCT; C: Observation after allo-SCT; O: Overall survival rates. Condition being studied: Hypomethylating agents (HMAs) seem to have a range of properties favorable to post-allogeneic hematopoietic stem cell transplantation (allo-SCT) maintenance in acute myeloid leukemia (AML) patients. This meta-analysis was performed to review all relevant studies to compare the outcomes of patients undergoing allo-SCT for AML or MDS receiving HMA maintenance therapy with observation only. Information sources: The systematic search of the Embase and MEDLINE databases identified 4,416 articles, from which 512 duplicates were removed. This resulted in 3,904 articles available for title and abstract review. Subsequently, 3,875 articles were excluded as the article type and study design did not fulfill the inclusion criteria, or there was no report on a primary outcome of interest. The remaining 29 articles underwent full-length review and 18 of those were excluded for the aforementioned reasons. Ultimately, the eligibility criteria for our meta-analysis were met by 11 studies: 2 RCTs, 1 prospective cohort study, and 8 retrospective cohort studies.

scholarly journals FLAMSA-RIC for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis

10.3390/jcm8091437 â—½  
2019 â—½  
Vol 8 (9) â—½  
pp. 1437 â—½  
Author(s):  
Weerapat Owattanapanich â—½  
Patompong Ungprasert â—½  
Verena Wais â—½  
Smith Kungwankiattichai â—½  
Donald Bunjes â—½  
...  
Keyword(s):  
Acute Myeloid Leukemia â—½  
Stem Cell â—½  
High Risk â—½  
Stem Cell Transplantation â—½  
Cell Transplantation â—½  
Myeloid Leukemia â—½  
Meta Analysis â—½  
Chronic Gvhd â—½  
Hematopoietic Stem â—½  
Acute Myeloid

Reduced-intensity conditioning (RIC) regimens are established options for hematopoietic stem cell transplantation (HSCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, the efficacy of RIC regimens for patients with high-risk disease is limited. The addition of a fludarabine, amsacrine, and cytarabine (FLAMSA)-sequential conditioning regimen was introduced for patients with high-risk MDS and AML to combine a high anti-leukemic activity with the advantages of RIC. The current systematic literature review and meta-analysis was conducted with the aim of identifying all cohort studies of patients with AML and/or MDS who received FLAMSA-RIC to determine its efficacy and toxicity. Out of 3044 retrieved articles, 12 published studies with 2395 overall patients (18.1–76.0 years; 96.8% AML and 3.2% MDS; follow-up duration of 0.7–145 months; 50.3% had active AML disease before HSCT) met the eligibility criteria and were included in the meta-analysis. In the pooled analysis, the 1- and 3-year overall survival (OS) rates were 59.6% (95% confidence interval (CI), 47.9–70.2%) and 40.2% (95% CI, 28.0–53.7%), respectively. The pooled 3-year OS rate of the patients who achieved CR1 or CR2 prior to HSCT was 60.1% (95% CI, 55.1–64.8%) and the percentage of those with relapse or refractory disease was 27.8% (95% CI, 23.3–32.8%). The pooled 3-year leukemia-free survival (LFS) rate was 39.3% (95% CI, 26.4–53.9%). Approximately 29% of the patients suffered from grades 2–4 acute graft-versus-host disease (GVHD), while 35.6% had chronic GVHD. The pooled 1- and 3-year non-relapse mortality (NRM) rates were 17.9% (95% CI, 16.1–19.8%) and 21.1% (95% CI, 18.8–23.7%), respectively. Our data indicates that the FLAMSA-RIC regimen is an effective and well-tolerated regimen for HSCT in patients with high-risk AML and MDS.

scholarly journals Allogeneic Stem Cell Transplantation in Treatment Related and Secondary Acute Myeloid Leukemia and Myelodysplastic Syndrome: Ohsu Experience

2021 â—½  
Vol 27 (3) â—½  
pp. S159-S161
Author(s):  
Luke Benjamin Fletcher â—½  
Staci Williamson â—½  
Jessie Myers â—½  
Curtis Andrew Lachowiez â—½  
Charles Dibb â—½  
...  
Keyword(s):  
Acute Myeloid Leukemia â—½  
Stem Cell â—½  
Stem Cell Transplantation â—½  
Myelodysplastic Syndrome â—½  
Cell Transplantation â—½  
Allogeneic Stem Cell Transplantation â—½  
Myeloid Leukemia â—½  
Secondary Acute Myeloid Leukemia â—½  
Acute Myeloid

scholarly journals Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome

2005 â—½  
Vol 37 (2) â—½  
pp. 183-189 â—½  
Author(s):  
N Kröger â—½  
â—½  
R Brand â—½  
A van Biezen â—½  
J-Y Cahn â—½  
...  
Keyword(s):  
Acute Myeloid Leukemia â—½  
Stem Cell â—½  
Stem Cell Transplantation â—½  
Myelodysplastic Syndrome â—½  
Cell Transplantation â—½  
Autologous Stem Cell Transplantation â—½  
Myeloid Leukemia â—½  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document